These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 22490510)

  • 1. Programmable bio-nano-chip systems for serum CA125 quantification: toward ovarian cancer diagnostics at the point-of-care.
    Raamanathan A; Simmons GW; Christodoulides N; Floriano PN; Furmaga WB; Redding SW; Lu KH; Bast RC; McDevitt JT
    Cancer Prev Res (Phila); 2012 May; 5(5):706-16. PubMed ID: 22490510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multiplexable, microfluidic platform for the rapid quantitation of a biomarker panel for early ovarian cancer detection at the point-of-care.
    Shadfan BH; Simmons AR; Simmons GW; Ho A; Wong J; Lu KH; Bast RC; McDevitt JT
    Cancer Prev Res (Phila); 2015 Jan; 8(1):37-48. PubMed ID: 25388014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bead-based ELISA for validation of ovarian cancer early detection markers.
    Scholler N; Crawford M; Sato A; Drescher CW; O'Briant KC; Kiviat N; Anderson GL; Urban N
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2117-24. PubMed ID: 16609024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Highly accurate detection of ovarian cancer using CA125 but limited improvement with serum matrix-assisted laser desorption/ionization time-of-flight mass spectrometry profiling.
    Tiss A; Timms JF; Smith C; Devetyarov D; Gentry-Maharaj A; Camuzeaux S; Burford B; Nouretdinov I; Ford J; Luo Z; Jacobs I; Menon U; Gammerman A; Cramer R
    Int J Gynecol Cancer; 2010 Dec; 20(9):1518-24. PubMed ID: 21370595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An amplified comparative fluorescence resonance energy transfer immunosensing of CA125 tumor marker and ovarian cancer cells using green and economic carbon dots for bio-applications in labeling, imaging and sensing.
    Hamd-Ghadareh S; Salimi A; Fathi F; Bahrami S
    Biosens Bioelectron; 2017 Oct; 96():308-316. PubMed ID: 28525848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Programmable Bio-nanochip Platform: A Point-of-Care Biosensor System with the Capacity To Learn.
    McRae MP; Simmons G; Wong J; McDevitt JT
    Acc Chem Res; 2016 Jul; 49(7):1359-68. PubMed ID: 27380817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integration of cell phone imaging with microchip ELISA to detect ovarian cancer HE4 biomarker in urine at the point-of-care.
    Wang S; Zhao X; Khimji I; Akbas R; Qiu W; Edwards D; Cramer DW; Ye B; Demirci U
    Lab Chip; 2011 Oct; 11(20):3411-8. PubMed ID: 21881677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lab-on-a-Disc for Point-of-Care Infection Diagnostics.
    Sunkara V; Kumar S; Sabaté Del Río J; Kim I; Cho YK
    Acc Chem Res; 2021 Oct; 54(19):3643-3655. PubMed ID: 34516092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation of a Novel Biomarker Panel for the Detection of Ovarian Cancer.
    Leung F; Bernardini MQ; Brown MD; Zheng Y; Molina R; Bast RC; Davis G; Serra S; Diamandis EP; Kulasingam V
    Cancer Epidemiol Biomarkers Prev; 2016 Sep; 25(9):1333-40. PubMed ID: 27448593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Programmable bio-nano-chip system: a flexible point-of-care platform for bioscience and clinical measurements.
    McRae MP; Simmons GW; Wong J; Shadfan B; Gopalkrishnan S; Christodoulides N; McDevitt JT
    Lab Chip; 2015 Oct; 15(20):4020-31. PubMed ID: 26308851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nano-bio-chips for high performance multiplexed protein detection: determinations of cancer biomarkers in serum and saliva using quantum dot bioconjugate labels.
    Jokerst JV; Raamanathan A; Christodoulides N; Floriano PN; Pollard AA; Simmons GW; Wong J; Gage C; Furmaga WB; Redding SW; McDevitt JT
    Biosens Bioelectron; 2009 Aug; 24(12):3622-9. PubMed ID: 19576756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complementary Longitudinal Serum Biomarkers to CA125 for Early Detection of Ovarian Cancer.
    Simmons AR; Fourkala EO; Gentry-Maharaj A; Ryan A; Sutton MN; Baggerly K; Zheng H; Lu KH; Jacobs I; Skates S; Menon U; Bast RC
    Cancer Prev Res (Phila); 2019 Jun; 12(6):391-400. PubMed ID: 30967390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longitudinal screening algorithm that incorporates change over time in CA125 levels identifies ovarian cancer earlier than a single-threshold rule.
    Drescher CW; Shah C; Thorpe J; O'Briant K; Anderson GL; Berg CD; Urban N; McIntosh MW
    J Clin Oncol; 2013 Jan; 31(3):387-92. PubMed ID: 23248253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ultrasensitive bioassay of epitope of Mucin-16 protein (CA 125) in human plasma samples using a novel immunoassay based on silver conductive nano-ink: A new platform in early stage diagnosis of ovarian cancer and efficient management.
    Jafari M; Hasanzadeh M; Solhi E; Hassanpour S; Shadjou N; Mokhtarzadeh A; Jouyban A; Mahboob S
    Int J Biol Macromol; 2019 Apr; 126():1255-1265. PubMed ID: 30615961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.
    Baron AT; Boardman CH; Lafky JM; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ
    Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):306-18. PubMed ID: 15734951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alternative antibody for the detection of CA125 antigen: a European multicenter study for the evaluation of the analytical and clinical performance of the Access OV Monitor assay on the UniCel Dxl 800 Immunoassay System.
    Holdenrieder S; Molina R; Gion M; Gressner A; Troalen F; Auge JM; Zancan M; Wycislo M; Stieber P
    Clin Chem Lab Med; 2008; 46(5):588-99. PubMed ID: 18598201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative analysis of CA125, tissue polypeptide specific antigen, and soluble interleukin-2 receptor alpha levels in sera, cyst, and ascitic fluids from patients with ovarian carcinoma.
    Sedlaczek P; Frydecka I; Gabryś M; Van Dalen A; Einarsson R; Harłozińska A
    Cancer; 2002 Nov; 95(9):1886-93. PubMed ID: 12404282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble interleukin-2 receptor alpha is elevated in sera of patients with benign ovarian neoplasms and epithelial ovarian cancer.
    Hurteau JA; Woolas RP; Jacobs IJ; Oram DC; Kurman CC; Rubin LA; Nelson DL; Berchuck A; Bast RC; Mills GB
    Cancer; 1995 Nov; 76(9):1615-20. PubMed ID: 8635066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ultrasensitive immunoassay of carcinoma antigen 125 in untreated human plasma samples using gold nanoparticles with flower like morphology: A new platform in early stage diagnosis of ovarian cancer and efficient management.
    Hasanzadeh M; Sahmani R; Solhi E; Mokhtarzadeh A; Shadjou N; Mahboob S
    Int J Biol Macromol; 2018 Nov; 119():913-925. PubMed ID: 30081127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A combined biomarker panel shows improved sensitivity for the early detection of ovarian cancer allowing the identification of the most aggressive type II tumours.
    Russell MR; Graham C; D'Amato A; Gentry-Maharaj A; Ryan A; Kalsi JK; Ainley C; Whetton AD; Menon U; Jacobs I; Graham RLJ
    Br J Cancer; 2017 Aug; 117(5):666-674. PubMed ID: 28664912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.